Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Colorectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Nasopharyngeal Carcinoma 1MSI-H 1Lung Neoplasms 1IIIA Stage Non-small Cell Lung Cancer 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Advanced Solid Tumors 1

Interventions

Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1sintilimab 1atezolizumab 1Transurethral Resection of Prostate 1Tomography, X-Ray Computed 1Oxaliplatin 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Cancer Metastatic × sintilimab × Clear all
NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sun Yat-sen University

Phase 1/2 Active not recruiting
36 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡